Medically reviewed by Dr. Shweta Agarwal, MBBS, DGO. Last updated: June 2026.
Information on this page is educational and does not replace a medical consultation. Outcomes depend on individual clinical factors.
In Marathi, ovarian reserve testing is sometimes referred to as अंडाशय राखीव चाचणी — a term your doctor may use during consultation.
What does ovarian reserve testing actually measure — and what does it not?
Ovarian reserve testing measures egg quantity — how many eggs are likely to remain in the ovaries at the time of testing. AMH reflects the pool of small growing follicles producing the hormone; AFC counts those small follicles directly on ultrasound. A higher result suggests more eggs in reserve; a lower result suggests fewer.
What ovarian reserve testing does not measure is equally important to understand:
- It does not measure egg quality. The ability of an egg to fertilise normally and develop into a healthy embryo is primarily determined by age, not by AMH or AFC. A woman with a lower AMH can still have good-quality eggs, particularly if she is younger.
- It is not a direct predictor of natural conception. A lower reserve means fewer eggs available over time, but many women with reduced reserve conceive naturally or with assistance. AMH and AFC are planning tools, not verdicts.
- It does not tell you precisely how long you have. It gives a snapshot of current reserve relative to age-adjusted expectations; it does not forecast exactly when fertility will decline further.
For a thorough explanation of what low AMH means in practice, see the low AMH condition page and the AMH meaning and low AMH explained blog.
What is the AMH blood test, and how does it work?
AMH (Anti-Müllerian Hormone) is a protein produced by the granulosa cells of small ovarian follicles. Because these follicles are in an early, growing stage and are present throughout the cycle, AMH levels in the blood remain relatively stable from day to day. This stability gives AMH a practical clinical advantage: the test can be drawn on any day of the menstrual cycle, without the need to time it to Day 2 or Day 3 as FSH tests require.
The test is a straightforward blood draw — the same as any routine blood sample taken from the arm. No fasting is required. The sample is processed in our in-house laboratory.
Your result sheet will indicate which unit and reference range apply for the assay used, and your doctor will explain what your specific result means for you.
What is the antral follicle count (AFC), and why is it done alongside AMH?
The antral follicle count is a transvaginal ultrasound assessment that directly counts the small, fluid-filled follicles visible in both ovaries at a particular moment in the cycle. These follicles — typically between two and ten millimetres in diameter — represent the cohort of eggs available in that cycle, and their total number reflects the broader reserve.
AFC is usually performed early in the menstrual cycle (day 2–4 is conventional, though the optimal timing can vary slightly). The scan is done transvaginally, takes approximately ten minutes, and is the same type of pelvic ultrasound used routinely in a fertility evaluation.
AMH and AFC measure the same underlying biological reality — the follicle pool — via different methods: one through a blood marker, one through direct imaging. Because each has its own sources of variation, using both together gives a more complete and reliable picture than either test alone. A result that appears unexpectedly low on one test is more meaningful when it is confirmed by the other, and discordant results prompt closer interpretation.
When is ovarian reserve testing recommended?
Ovarian reserve testing is appropriate in several clinical situations — it is not only for women already diagnosed with infertility:
- As part of the initial fertility workup for any woman investigating difficulty conceiving. It is a standard component of the complete fertility diagnostics evaluation.
- Before IVF, to plan the stimulation protocol and medication doses. AMH and AFC together allow the clinical team to individualise the approach to each patient's likely ovarian response.
- Before egg freezing (oocyte cryopreservation), to assess whether the current reserve is sufficient for a collection cycle and to counsel on the likely number of eggs retrievable. See egg freezing.
- When cycles are irregular or shorter than usual, as this can sometimes indicate declining reserve.
- After ovarian surgery — for endometriomas, dermoid cysts, or other ovarian pathology — to assess whether the procedure has affected the remaining follicle pool.
- After chemotherapy or radiation, to understand residual ovarian function before further fertility planning.
- For age-related fertility planning: women in their late twenties or thirties who want to understand their current reserve before deciding when to start a family.
- When a family history of early menopause is present.
How is the testing performed at Aansh?
The two tests are usually scheduled together for efficiency, though AMH alone can be done at any point in the cycle:
AMH blood test: A blood sample is drawn from the arm — no preparation is required. You can eat and drink normally beforehand. There is no requirement to attend on a particular cycle day, which makes it easy to book at short notice or alongside an existing appointment. The sample is analysed in our in-house laboratory.
Antral follicle count (AFC): A transvaginal ultrasound, preferably performed early in the cycle (typically day 2–4). You will be asked to empty your bladder beforehand. The scan takes approximately ten to fifteen minutes. The sonographer counts the visible antral follicles in both ovaries, and the findings are recorded alongside any other relevant uterine or ovarian observations.
Results from both tests are reviewed by Dr. Shweta Agarwal in the context of your age, menstrual history, and reason for testing. A single number is not interpreted in isolation.
How are results expressed, and what does "high" or "low" mean at a broad level?
AMH results are compared against age-adjusted reference ranges, because a value that is normal for a woman in her twenties may indicate reduced reserve in a woman in her late thirties. The ranges are also assay-dependent — different laboratory platforms can produce results on slightly different numeric scales, which is why direct comparison between results from different labs requires care.
As a general orientation:
- A result within the expected range for your age suggests reserve is broadly adequate.
- A result below the age-adjusted lower limit suggests diminished ovarian reserve and may prompt earlier or more proactive fertility planning.
- A high result can indicate a larger-than-average follicle pool, which is sometimes associated with PCOS and carries its own clinical implications (see below).
For age-specific reference ranges explained in detail, see our AMH levels by age — normal range guide.
Similarly, AFC results are interpreted in the context of age and the AMH finding, rather than against a single fixed number.
If you have results from two labs reported on different scales, your doctor will convert and compare appropriately.
How are the results used in practice? IVF stimulation, egg freezing, and PCOS
The primary clinical use of AMH and AFC is to individualise treatment planning. This is what the results directly inform:
IVF ovarian stimulation protocol: The starting doses and type of stimulation medications used in an IVF cycle are calibrated to the likely ovarian response. A lower AMH or AFC signals that a more carefully managed protocol may be needed, whereas a higher result may indicate that the stimulation dose should be conservative to avoid over-response.
Freeze-all and poor-responder strategy: When reserve is low, the clinical team may plan around the expected number of eggs from the outset — for example, considering a freeze-all approach to allow time to accumulate embryos, or counselling on realistic expectations for egg number in a single cycle. These decisions are made in the context of your full picture, not AMH alone.
Egg freezing counselling: AMH and AFC are central to the conversation about whether egg freezing is timely and likely to yield a useful number of eggs. They help set realistic expectations and inform the decision about whether to proceed now or reassess. See egg freezing for more.
High AMH and PCOS risk: A markedly elevated AMH — particularly when AFC also shows numerous small follicles and the ovaries have a polycystic appearance on ultrasound — is associated with PCOS (polycystic ovary syndrome). In an IVF context, this is clinically important because women with PCOS and high AMH are at higher risk of ovarian hyperstimulation syndrome (OHSS), which means the stimulation protocol must be carefully managed. This is not a reason to avoid treatment; it is a reason to plan it precisely.
What ovarian reserve testing does not tell you
It is worth being explicit about the limitations, because the test is sometimes misunderstood:
- AMH and AFC do not measure egg quality. Egg quality — the ability of an egg to fertilise, develop into an embryo, and implant — is primarily age-driven. A lower AMH does not mean the remaining eggs are abnormal; it means there are fewer of them.
- A low result is not a diagnosis of infertility and is not a guarantee that treatment will not work. Many women with low or reduced AMH conceive with appropriate treatment. Outcomes depend on multiple factors, of which AMH is one.
- A normal or high AMH does not guarantee fertility or IVF success. Reserve being adequate does not resolve other factors — tubal patency, uterine health, sperm quality — that also matter.
- Results can vary between tests and laboratories. Minor fluctuations between measurements can reflect natural variation, assay differences, or the timing of the AFC scan. Trend over time is more informative than a single measurement.
What is the cost of AMH and AFC testing?
The test is typically a modest standalone cost within a broader fertility workup. Final cost depends on individual clinical evaluation — see Costs & EMI for current pricing. You are informed of the cost before the test is done. For treatment that may follow, transparent written estimates are provided, and 0% EMI options (3–24 months) are available.